Reports related to this article:
Project(s): View 1 related project in PECWeb
Plant(s): View 1 related plant in PECWeb
Released November 20, 2019 | GALWAY, IRELAND
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Takeda Pharmaceutical (Osaka, Japan) has officially opened its new manufacturing plant in Singen, Germany, for its planned dengue vaccine, TAK-003, which is in Phase 3 trials.
The vaccine plant, which cost 130 million euro ($143 million), will be used for formulation, fill, finish and secondary packaging of the dengue vaccine candidate, starting with the packaging line. Takeda will employ up to 200 employees at the plant. Construction activities started at the end of 2016, with the goal to launch end-to-end production closer to successful licensing for the dengue vaccine. Industrial Info is tracking almost $400 million in project activity by Takeda.
According to Takeda, initial data for the vaccine published in the New England Journal of Medicine found that it had an 80% success rate for protection against virologically-confirmed dengue (VCD) across a sample of 20,000 participants. The World Health Organization (WHO) has claimed that dengue is the fastest spreading mosquito-borne viral disease, which is estimated to cause approximately 390 million infections and 20,000 deaths globally each year.
"This project is one of our most significant investments within our global manufacturing network," explained Thomas Wozniewski, global manufacturing and supply officer. "We are proud to open this new, state-of-the-art sterile manufacturing plant, which combines a high degree of automation with the most advanced digital and data-driven technologies. Our Singen site has been selected for this investment as our employees have vast experience in lyophilization technology, which is key for the manufacturing process of Takeda's dengue vaccine candidate."
"This new production facility expands Takeda's global footprint in vaccine manufacturing beyond Hikari, Japan, and reinforces our capability to manufacture at scale and meet the global demand that we anticipate for this vaccine," said Rajeev Venkayya, MD, president of the Global Vaccine Business unit at Takeda.
In related news, Takeda has agreed to sell some over-the-counter and prescription drugs in Russia, Georgia and several other Commonwealth countries to Germany's Stada for $660 million. It forms part of the company's plan to divest itself of up to $10 billion in assets following the completion of its $62 billion takeover of Shire plc in January. In May, Swiss pharmaceutical company Novartis International AG (NYSE:NVS) (Basel, Switzerland) agreed to pay $5.3 billion to purchase a number of eye-disease medicines from Takeda Pharmaceutical. Separately, Takeda agreed to sell its surgical patch, Tachosil, to Ethicon Incorporated for $400 million. Last month it announced its sale of non-core assets in countries spanning the Near East, Middle East and Africa to Acino for more than $200 million. For additional information, see May 27, 2019, article - Novartis Snaps Up Xiidra Eye Drops in $5.3 Billion Deal.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
The vaccine plant, which cost 130 million euro ($143 million), will be used for formulation, fill, finish and secondary packaging of the dengue vaccine candidate, starting with the packaging line. Takeda will employ up to 200 employees at the plant. Construction activities started at the end of 2016, with the goal to launch end-to-end production closer to successful licensing for the dengue vaccine. Industrial Info is tracking almost $400 million in project activity by Takeda.
According to Takeda, initial data for the vaccine published in the New England Journal of Medicine found that it had an 80% success rate for protection against virologically-confirmed dengue (VCD) across a sample of 20,000 participants. The World Health Organization (WHO) has claimed that dengue is the fastest spreading mosquito-borne viral disease, which is estimated to cause approximately 390 million infections and 20,000 deaths globally each year.
"This project is one of our most significant investments within our global manufacturing network," explained Thomas Wozniewski, global manufacturing and supply officer. "We are proud to open this new, state-of-the-art sterile manufacturing plant, which combines a high degree of automation with the most advanced digital and data-driven technologies. Our Singen site has been selected for this investment as our employees have vast experience in lyophilization technology, which is key for the manufacturing process of Takeda's dengue vaccine candidate."
"This new production facility expands Takeda's global footprint in vaccine manufacturing beyond Hikari, Japan, and reinforces our capability to manufacture at scale and meet the global demand that we anticipate for this vaccine," said Rajeev Venkayya, MD, president of the Global Vaccine Business unit at Takeda.
In related news, Takeda has agreed to sell some over-the-counter and prescription drugs in Russia, Georgia and several other Commonwealth countries to Germany's Stada for $660 million. It forms part of the company's plan to divest itself of up to $10 billion in assets following the completion of its $62 billion takeover of Shire plc in January. In May, Swiss pharmaceutical company Novartis International AG (NYSE:NVS) (Basel, Switzerland) agreed to pay $5.3 billion to purchase a number of eye-disease medicines from Takeda Pharmaceutical. Separately, Takeda agreed to sell its surgical patch, Tachosil, to Ethicon Incorporated for $400 million. Last month it announced its sale of non-core assets in countries spanning the Near East, Middle East and Africa to Acino for more than $200 million. For additional information, see May 27, 2019, article - Novartis Snaps Up Xiidra Eye Drops in $5.3 Billion Deal.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Our European headquarters are located in Galway, Ireland. Follow IIR Europe on: Facebook - Twitter - LinkedIn For more information on our European coverage send inquiries to info@industrialinfo.eu or visit us online at Industrial Info Europe.
